Lexaria Bioscience Corp. (OTCMKTS:LXRP – Get Free Report) fell 10.7% on Monday . The stock traded as low as $0.21 and last traded at $0.22. 2,151,500 shares were traded during trading, an increase of 254% from the average session volume of 608,350 shares. The stock had previously closed at $0.25.
Lexaria Bioscience Stock Performance
The business’s 50-day moving average price is $0.22. The company has a quick ratio of 8.01, a current ratio of 8.52 and a debt-to-equity ratio of 0.01.
About Lexaria Bioscience
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries.
Featured Stories
- Five stocks we like better than Lexaria Bioscience
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- What is MarketRank™? How to Use it
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
